A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
Recruiting
- Conditions
- Lymphoma
- Registration Number
- NCT04837222
- Lead Sponsor
- Takeda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Inclusion Criteria:<br><br> 1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial<br> treatment with brentuximab vedotin) or to be received with brentuximab vedotin.<br><br> 2. CD30-positive lymphoma by INV (any CD30 expression)<br><br>Exclusion Criteria:<br><br> 1. Who currently participates in or with plan to participate in any interventional<br> clinical trial.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants Reporting one or More Serious Adverse Events (SAEs)
- Secondary Outcome Measures
Name Time Method Number of Participants Reporting one or More Adverse Events (AEs);Number of Participants Reporting one or More Adverse Drug Reactions (ADRs);Number of Participants With Dose Adjustments During the Study;Number of Participants Based on Usage of Brentuximab Vedotin;Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice;Number of Participants Based on Disease Characteristics;Time to Next Treatment (TTNT);Objective Response Rate (ORR);Duration of Response (DOR);Progression Free Survival (PFS) Rate;Overall Survival (OS) Rate;Change From Baseline in Quality of Life (QoL) Assessed Using Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire Version 4;Cost-effectiveness Ratio